MENU
Showcases Stock ranks Forex

Ironwood Pharmaceuti (IRWD)
8.71  0.09 (1.04%) 03-28 16:00
Open: 8.7 Pre. Close: 8.62
High: 9.005 Low: 8.595
Volume: 2,612,254 Market Cap: 1,363(M)
Stock Technical Analysis
Overall:     
Target: Six months: 14.68
One year: 17.82
Support: Support1: 8.21
Support2: 6.83
Resistance: Resistance1: 12.57
Resistance2: 15.26
Pivot: 8.77
Moving Averages: MA(5): 8.55
MA(20): 8.84
MA(100): 11.40
MA(250): 10.63
MACD: MACD(12,26): -1.01
Signal(12,26,9): -1.14
%K %D: %K(14,3): 28.56
%D(3): 18.96
RSI: RSI(14): 34.49
52-Week: High: 15.7
Low: 8.07
Change(%): -16.4
Average Vol(K): 3-Month: 4968
10-Days: 5353
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 9.025 - 9.068 9.068 - 9.108
Low: 8.495 - 8.545 8.545 - 8.59
Close: 8.629 - 8.71 8.71 - 8.783
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ IRWD ] has closed above bottom band by 43.9%. Bollinger Bands are 66.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Stock chart
Stock News
Thu, 28 Mar 2024
Critical Analysis: Rocket Pharmaceuticals (NASDAQ:RCKT) vs. Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World

Wed, 27 Mar 2024
Public Employees Retirement System of Ohio Makes New $862000 Investment in Ironwood Pharmaceuticals, Inc ... - Defense World

Mon, 25 Mar 2024
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Movies Canada

Sat, 23 Mar 2024
Zacks Research Analysts Increase Earnings Estimates for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World

Mon, 18 Mar 2024
What is the Market's View on Ironwood Pharmaceuticals, Inc. (IRWD) Stock's Price and Volume Trends Monday? - InvestorsObserver

Thu, 29 Feb 2024
Ironwood Pharmaceuticals Stock Just Erased Its 38% Three-Month Charge — Here's Why - Investor's Business Daily

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty & Generic
Shares Out. (M) 156.53
Shares Float (M) 137.03
% Held by Insiders 2.08
% Held by Institutions 108.88
Shares Short (K) 15510
Shares Short Prior Month (K) 14460
Stock Financials
EPS -6.450
Book Value (p.s.) -2.210
Profit Margin -226.37
Operating Margin 3.16
Return on Assets (ttm) 13.4
Return on Equity (ttm) -674.0
Qtrly Rev. Growth 9.7
Gross Profit (p.s.)
Sales Per Share 2.828
EBITDA (p.s.) 1.085
Qtrly Earnings Growth
Operating Cash Flow (M) 183.43
Levered Free Cash Flow (M) 186.79
Stock Valuation
PE Ratio -1.35
PEG Ratio 0.18
Price to Book value -3.94
Price to Sales 3.08
Price to Cash Flow 7.43
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android